Regulus Therapeutics Inc
NASDAQ:RGLS
Intrinsic Value
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of RGLS.
Regulus Therapeutics Inc's market capitalization is 146m USD.
RGLS stock price is 2.23 USD.
RGLS.
RGLS. Open DCF Valuation
RGLS. Open Relative Valuation
RGLS has upside potential of 184% compared to the average analyst price target.
Open Wall St Estimates
RGLS's ROE (Return on Equity) has significantly decreased in the last 3 years from -75% to -110%, and is approaching profitability.
RGLS's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -217% to -439%, and is approaching profitability.
RGLS has negative Operating Income for the last twelve months.
RGLS has negative Net Income for the last twelve months.
RGLS's ROE (Return on Equity) for the past 12 months is negative and is equal to -110%.
RGLS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -439%.
RGLS has negative Free Cash Flow for the last twelve months.
RGLS's long-term assets (31m USD) exceed its long-term liabilties (10m USD).
RGLS's short-term assets (28m USD) exceed its short-term liabilties (9m USD).
RGLS has negative three-year average ROE (Return on Equity): -80%. The company is not efficient at transforming stockholders' equity into net income.
RGLS has negative three-year average ROIC (Return on Invested Capital): -379%. The company is not efficient at using invested capital to generate operating income.
RGLS's D/E (Debt to Equity) is very low and is equal to 0.
RGLS's Altman Z-Score is very low and is equal to -21.61.
RGLS doesn't generate enough operating income (-31m USD) to safely cover interest payments on its debt (447k USD).
Fundamental Analysis
Regulus Therapeutics Inc
Balance Sheet Decomposition
Regulus Therapeutics Inc
| Current Assets | 28.2m |
| Cash & Short-Term Investments | 23.8m |
| Other Current Assets | 4.4m |
| Non-Current Assets | 2.6m |
| PP&E | 2.5m |
| Intangibles | 33k |
| Current Liabilities | 8.5m |
| Accounts Payable | 204k |
| Accrued Liabilities | 4.6m |
| Other Current Liabilities | 3.7m |
| Non-Current Liabilities | 1.1m |
| Other Non-Current Liabilities | 1.1m |
Earnings Waterfall
Regulus Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-31.1m
USD
|
|
Operating Income
|
-31.1m
USD
|
|
Other Expenses
|
1.1m
USD
|
|
Net Income
|
-30m
USD
|
Free Cash Flow Analysis
Regulus Therapeutics Inc
RGLS Profitability Score
Profitability Due Diligence
Regulus Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Regulus Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
RGLS Solvency Score
Solvency Due Diligence
Regulus Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Regulus Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RGLS Price Targets Summary
Regulus Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
RGLS
is 6.32 USD
with a low forecast of 2.02 USD and a high forecast of 11.55 USD.
Ownership
RGLS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RGLS Price
Regulus Therapeutics Inc
| Average Annual Return | -30.11% |
| Standard Deviation of Annual Returns | 46.43% |
| Max Drawdown | -96% |
| Market Capitalization | 146m USD |
| Shares Outstanding | 65 465 300 |
| Percentage of Shares Shorted | 12.18% |
Company Profile
Regulus Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 26 full-time employees. The company went IPO on 2012-10-04. The firm is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s product lead product candidates include RG-012 and RGLS8429. The firm is focused on evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). The firm also focuses on the evaluation of its designed compounds that inhibit miR-155 activity in microglia cell-based assays and in animal models of the disease, to identify potential candidates to advance into further studies. In addition to its focus on genetic kidney disease, the Company is focused on the research in technology to treat central nervous system (CNS) disease.
You don't have any saved screeners yet
